Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

Sarepta Therapeutics SRPT announced that the FDA has granted platform-technology designation to its viral vector rAAVrh74, ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

A Sarepta police officer has been arrested in connection with an incident where a dog was shot and killed last month.

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

The Webster Parish Sheriff's Office is investigating two officers in two different towns accused of shooting dogs.

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

A Sarepta police officer has been arrested in connection with an incident where a dog was shot and killed last month.

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT), Tuesday said that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Elevidys for the treatment of Duchenne muscular ...